Nuclear Repressors in Genomic Control of Healthful Obesity

Information

  • Research Project
  • 10367520
  • ApplicationId
    10367520
  • Core Project Number
    R01DK108987
  • Full Project Number
    2R01DK108987-06
  • Serial Number
    108987
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    5/10/2016 - 8 years ago
  • Project End Date
    7/31/2025 - 4 months from now
  • Program Officer Name
    SILVA, CORINNE M
  • Budget Start Date
    9/17/2021 - 3 years ago
  • Budget End Date
    7/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    06
  • Suffix
  • Award Notice Date
    9/17/2021 - 3 years ago
Organizations

Nuclear Repressors in Genomic Control of Healthful Obesity

PROJECT SUMMARY Non-alcoholic fatty liver disease (NAFLD) afflicts nearly a quarter of Americans and is projected to become the leading cause of end-stage liver disease in the next decade. It is driven by overnutrition, disproportionately occurs in men, and is linked to derangements in liver lipid and sterol metabolism. The molecular determinants that control NAFLD and its sex-bias are incompletely understood. Using conditional genetic engineering, we have identified a profound role for the transcription factor B cell lymphoma 6 (BCL6) to direct sexually dimorphic transcription in hepatocytes. Herein, we propose to comprehensively dissect the transcriptional regulatory mechanisms of BCL6 underlying its sex-specific programming and the functional implications of hepatocyte Bcl6 on fatty liver disease and whole body metabolism. In Aim 1, we will test the impact of BCL6 on chromatin looping and histone modification, its sex-specific modes of recruitment to chromatin, and coregulation with estrogen receptor alpha. In Aim 2, we define the functional role of Bcl6 in the sexual dimorphism of NAFLD, its signaling through bile acid pathways, and its impact on fibrosis using loss- and gain-of-function studies in vivo. Together, these studies will reveal new molecular insights into the regulation of sexually dimorphic transcription and NAFLD.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
    280000
  • Indirect Cost Amount
    158212
  • Total Cost
    438212
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIDDK:438212\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CSME
  • Study Section Name
    Cell Signaling and Molecular Endocrinology Study Section
  • Organization Name
    NORTHWESTERN UNIVERSITY AT CHICAGO
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    005436803
  • Organization City
    CHICAGO
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    606114579
  • Organization District
    UNITED STATES